Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABT IDE For "End-To-End" Anastomoses Clip Expected In Q1 2000

This article was originally published in The Gray Sheet

Executive Summary

Advanced Bypass Technologies plans to pursue in the first quarter of 2000 an investigational device exemption to commence trials of a device for "end-to-end" sutureless anastomoses during coronary artery bypass graft surgery, the company says.

You may also be interested in...



St. Jude Will Tap Heart Valve Sales Reps For VSI Initial Anastomosis Product

St. Jude's strategy to capitalize long-term on its entry into the coronary artery treatment market through the $100 mil. acquisition of Vascular Science, Inc. will draw on established relationships between clinicians and the firm's Heart Valve division (cardiac surgeons) and the Daig electrophysiology division (interventionists).

St. Jude Will Tap Heart Valve Sales Reps For VSI Initial Anastomosis Product

St. Jude's strategy to capitalize long-term on its entry into the coronary artery treatment market through the $100 mil. acquisition of Vascular Science, Inc. will draw on established relationships between clinicians and the firm's Heart Valve division (cardiac surgeons) and the Daig electrophysiology division (interventionists).

Abbott Sews Up Puncture Seal Deal As Perclose Stock Falls On Recall Rumors

Abbott's July 8 acquisition of Perclose in a stock swap valued at about $680 mil. portends the firm's long-term strategy to expand its interventional cardiology presence at a tempered pace.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel